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Human immunodeficiency virus (HIV) infection is a major health problem worldwide.
Although it not curable, after the discovery of the antiretroviral drugs, it has become
treatable and the prognosis of the patients has improved. However, the high toxicity of
these drugs and the development of resistance have made necessary to find a different way
to combat the disease. Recently, a new kind of HIV inhibitor that blocks the fusion of the
protein and the viral membranes, has been discovered. Among these, Enfuvirtide (Fuzeon)
has been the first entry inhibitor to be accepted as a drug for human use.
The present work proposes the production of a dimer of Enfuvirtide which is thought to
become a stronger HIV entry inhibitor. Due to the high cost of Fuzeon production, it will
be obtained as part of a fusion protein expressed in bacterial cells and cleaved in order to
remove the peptide.
The preliminary steps previous to the expression of the fusion protein are shown.
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1. INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) was recognized in 1981, and the first
human immunodeficiency virus (HIV) was isolated 2 years laterxxvii. Since then, HIV has
spread worldwide, with an estimated 39.4 million infected people by the end of 2004xxviii.
HIV is a lentinovirus that is predominantly transmitted by sexual contact. It crosses the
mucosal epithelium and infects cells expressing the CD4 receptor, causing gradual
reduction of CD4+T cells, which leads to an increased sensitivity to opportunistic and
chronic infections and to oncogenesis.
Currently, there have been discovered more than 20 anti-HIV drugs. These antiretroviral
drugs (ARV) are categorized according to their mode of action. Nucleoside reverse
transcriptase inhibitors (NRTI) block the action of transcriptase reverse (TR) which is
responsible for transcribing the HIV-1 RNA genome to DNA, non-nucleoside reverse
transcriptase inhibitors (NNRTI) do not bind to the active site of TR but to a different site
and cause conformational changes that reduce the enzyme activity, and protease inhibitors
(PI) that bind the protease active site and inhibit the cleavage of viral proteinsxxix.
These ARV drugs are administered in combination (cocktails of 2 or 3 types) and this
highly active antiretroviral therapy (HAART) has improved the prognosis for HIV
patients. However, toxicity and resistance to some or all of the ARV drugs have been
found among patients.
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Recently, a new generation of inhibitors has been discovered. These HIV entry inhibitors
inhibit viral cell entry. The first drug approved of this kind was Enfuvirtide (Fuzeon,
formerly known as T-20 and DP-178)xxx. Among its advantages, this drug has activity
against multridrug resistant virus and limited side effects. In order to understand the mode
of action of Enfuvirtide is important to address the HIV entry pathway.
HIV fusion
HIV is an envelope virus that has spikes on its surface consisting of a protein complex that
comprises a cell-surface attachment glycoprotein, gp120xxxi, and a membrane spanning
protein, gp41. These are non-covalently linked and assemble into an oligomer (trimer).
Viral entry begins with the binding of gp120 to CD4 receptors on the surface of
lymphocytes. This step is followed by the binding to co-receptors (CXCR4 or CCR5) that
causes a conformational change on gp120 and exposes the transmembrane gp41xxxii. gp41
contains two heptad repeat regions: HR1 (proximal to the N terminus) and HR2 (proximal
to the C terminus)xxxiii, a N-terminal fusion peptide (FP) and a transmembrane region that
anchors the protein to the viral membrane. The FP inserts into the host cell membrane,
whereas the HR2 regions zips around a preformed trimer of HR1 regions in an antiparallel
fashion to form a six-helix bundle that attracts the viral and the membranes together for
fusion3,7,xxxiv. Because the fusion process does not occur immediately (formation of a pre-
hairpin intermediate step is believe to occurr), this process can be inhibited.
Enfurvitide (Fuzeon): An HIV entry inhibitor
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Enfuvirtide (Figure 1) is a 36 amino acid peptide that mimics a portion of the HR2 region
from gp41. It is thought that Enfuvirtide binds to the HR1 domain. This binding avoids the
formation of the 6-helix bundle by preventing HR2 from refolding antiparallel to HR13,6,7.
Some studies have shown that the pre-hairpin intermediate is the target of Enfuvirtidexxxv.
It is a highly potent and specific inhibitor in vitro and in vivo (IC50 of 1.5 ng per mL
blocking HIV-1LAI)7. Because of its extracelullar mechanism, Enfuvirtide is active against
HIV-1 strains with resistance to any of the three other classes of inhibitors. Besides, its
use in combination with other ARV has shown to be more efficient. The drug is supplied
by a dose of 90 mg/mL that is injected subcutaneously, twice a day8.
Figure 1. Structure of Enfuvirtide
Although the advantages that Enfuvirtide possesses, producing the lengthy peptide











































observe an antiviral effect in humans. Cheaper methods of production of the drug are
necessary in order to satisfy its demands.
Design of a potential HIV inhibitor: dimeric Enfuvirtide
Enfurvitide mimics the C-terminal sequence of gp41, and binds to the N-terminal sequence
(HR1 domain) inhibiting the fusion between the host and the viral membrane. Considering
that the N-peptide trimeric coiled coil contains three grooves that can be bound by C-
peptides, in this work, we propose the production of a dimer of Enfurvitide, which is
thought to bind to two of the grooves of the HR1 domain. This molecule is believed to
become a better inhibitor than the monomer itself.
In the dimer the peptides will be joined by a linker that contains amide and ether as
functional groups, and a terminal ketone. Polyether linkers are soluble in water. The linker






Scheme 1. Synthetic route proposed for the production of the linker. a) Formation of
the diamide linker, 1xxxvi. b) Formation of the terminal ketone linker, 2.
Production of Enfuvirtide by bacterial expression
Because the synthesis of Enfuvirtide is highly costly, we propose to obtain the peptide as
part of a fusion protein which will be produced by bacterial expressionxxxvii. The protein
partner is necessary because it serves to stabilize the peptide during expression of the
fusion protein in bacteria. Maltose-binding protein (MBP) will be used because it has been
proven to enhance the solubility of proteins expressed in E.colixxxviii. After expression,
Enfurvitide will be cleaved from the fusion protein using tobacco etch virus NIa protease
(TEV protease) (Scheme 2, a). TEV protease recognize a seven amino acid site and
cleaves between a glutamine and a serine or glycine. However, it has been proven that it
can cleave between a glutamine and a cysteine without loosing substantial activity13. The
formation of a N-terminal cysteine will be necessary in order to ligate chemoselectively











Scheme 2. a) Cleavage of the fusion protein by TEV protease. b) Chemoselective
ligation between the N-terminal cysteine of Fuzeon and the linker. Formation a of
thiazolidine linker.























Plasmids pET28a(+), pMAL-c2x and E.coli strain TOP10F’: F’  [lacIq, Tn10(TetR) mcrA
DImrr-hsdRMS-mcrBC) j80 lacZ DM15 DlacX74 deoR recA1 araD139 D(ara-leu)7679
galU galK rpsL(StrR) endA1 nupG] were purchased from New England BioLabs.
Primers 5’-Eco-TEV-Fuz (GCGCCGGCCcatatgTACACCTCCCTGATCCACTCC), 3’-
HindIII-Fuz (GCGCGCgaattcttaGAACCAGTTCCACAGGGAAGC), 5’-Eco-TEV-Fuz
(5’-GGC CCG GAA TTC GGA GGT GAA AAC CTG TAT   TTT CAG TGC GGT
TAC ACC TCC CTG-3’) and 3’-HindIII-Fuz (5’-GCG CGC AAG CTT TTA GAA CCA
GTT CCA CAG GGA AGC-3’) were purchased from MWG Biotech AG.
Enzymes Taq DNA Polymerase, T4 DNA Ligase, restriction endonucleases EcoRI and
HindIII, and CIP (calf intestinal alkaline phosphatase) were purchased from New England
BioLabs.
4,7,10-trioxa-1,13-tridecanediamine and (-)-ethyl L-lactate were purchased from Sigma-




1 L of Luria Bertani (LB) medium pH 7 was prepared by mixing 10 g peptone, 5 g yeast
extract and 10 g NaCl with deionized water.
Culture conditions
E.coli cells were grown in 5 mL LB medium containing 100 mg/mL ampicilin and shaking
at 37 °C overnight.
DNA purification conditions
After culturing E.coli cells the plasmid DNA was purified using Quigen Q1 Aprep Spin
Miniprep Kit (250) following the protocol: Plasmid DNA purification using the Q1 Aprep
Spin Miniprep Kit and a Microcentrifuge.
After fragment digestion the DNA was purified using Quigen QIAquick PCR purification
kit (250) following the protocol: QIAquick PCR purification using a microcentrifuge.
PCR reactions conditions
10x Thermo Pol Buffer B9004S, 200 mM dNTPs, 1 mM of each primer, 2 pg DNA
plasmid, 0.5 mL Taq DNA Polymerase and milliQ water were mixed in a PCR tube.
Controls were run using water instead of DNA plasmid. After an initial denaturation step
of  3  min  at  94 °C, 33 cycles of 45 s at 93 °C, 30 s at 55 °C and 2 min at 72 °C were
performed. A final extension step of 10 min at 72 °C completed the reaction.
DNA concentration analysis
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75 mL of 15x dilution solutions were used to determined DNA double strand
concentrations at 280 nm using DU 530, Life Science UV/Vis Spectrophotometer,
Beckman Coulter.
Tris-glycine SDS-polyacrylamide gels
17% acrylimide gel was prepared by mixing 2.5 mL of 1.5 M Tris-HCl pH 8.8, 0.05 mL of
20% SDS and 5.7 mL of a 30% acrylimide solution. The polymerization was initiated by
the addition of 160 mL of 10% APS (ammonium persulfate) and 6 mL of TEMED
(N,N,N’,N’-tetramethyethylenediamine).
2 mL stacking gel was prepared by mixing 1.4 mL of water, 0.33 mL of 30% acrylimide
solution, 0.25 mL of 1 M Tris-HCl pH 6.8 and 0.02 mL of 10% SDS. The polymerization
was initiated by the addition of 0.02 mL of 10% APS and 0.002 mL of TEMED.
Agarose gels
1% and 2% agarose gels were prepared dissolving 0.6 g and 1.2 g agarose, respectively, in
60 mL 1x TAE buffer (40 mM Tris-HCl, 1mM EDTA) and 6 mL of a 1 mg/mL ethidium
bromide. The gels were resolved using UV Transilluminator UVP.
Agarose gel extraction conditions
The gels were treated using the Quigen QIAEXII gel extraction kit (150) following the
protocol QIAEXII agarose gel extraction.
Single digestion reaction conditions
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Single digestions were carried out with 10 mL total volume using 1 mL 10x EcoRI buffer,
0.2 mL restriction enzyme, 8.6 mL pMAL-c2x plasmid DNA and milliQ water, for two
hours at 37 °C.
Double digestion reaction conditions
Digestions of plasmid DNA were carried out in 50 mL total volume, using 5 mL 10x
EcoRI buffer, 1 mL HindIII,  1mL EcoRI and 43 mL pMAL-c2x plasmid DNA, for two
hours at 37 °C. After this period of time 1 mL CIP was added. The enzymes were heat
inactivated at 65 °C. The DNA plasmid was purified running a 1% agarose gel.
Digestions of fragment DNA were carried out in 20 mL total volume, using 16 mL Fuzeon
DNA, 2 mL 10x EcoRI Buffer, 1 mL HindIII and 1 mL EcoRI. The DNA was purified
running a 2% agarose gel.
Ligation reaction conditions
For 20 mL total volume, 2 mL 10x T4 DNA ligase buffer, 1 mL T4 DNA ligase, 7 mL
pMAL-c2x plasmid DNA, the desire volume of Fuzeon DNA and milliQ water were
mixed. The reaction was left at room temperature for two hours. Controls were made
without insert.
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Transformation and electroporation conditions
70 mL E. coli TOP10F’cells extract and 1 mL of the ligase mixture were transformed using
an E.coli MicroPulser elctroporator (BioRAd) at the field strength of 1.8 kV/cm and pulse
duration of 3 ms, then incubated for 1 hour in 800 mL LB medium. Finally, the cells were
planted onto dishes containing LB medium and 100 mg/mL ampicilin.
2.2. Cloning of enfurvitide (Fuzeon) into pET-28a(+)
The gene encoding for Fuzeon was amplified using pET-28a(+) in which was previously
inserted by Theodore Gries in the Tolbert Lab. A 25 mL reaction was run following the
PCR reaction conditions. Fuzeon fragment was generated by using 5’ primer: 5’-Met-Fuz-
NdeI and 3’ primer: 3’-Fuz-St-EcoRI.  The presence of the Fuzeon DNA was determined
using a 2% agarose gel.
2.3. Construction of the Fusion Plasmid
In order to insert Fuzeon DNA into the polylinker site of pMAL-c2x, it was necessary to
clone it using different primers. The PCR reaction was run using 5’ primer: 5’-Eco-TEV-
Fuz and 3’ primer: 3’-HindIII-Fuz. Analysis and purification of Fuzeon DNA was made
using a 2 % agarose gel.
Plasmid pMAL-c2x and Fuzeon DNA were cut using EcoRI and HindIII restriction
enzymes, ligation was done using T4 DNA Ligase at two different volumes of insert (2
and 7 mL), followed by transformation of E.coli TOP10F’.
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2.4. TEV Protease cleavage
A solution of 200 mL 2.77 x 10-7 M*,xl TEV protease (5 mM DTT, 200 mM NaCl, 40%
glycerol) was placed into a 1000 MWCO dialysis bag. The bag was placed into 1 L 25
mM potassium phosphate pH 7.9 and left for three hours at room temperature. After this
period of time, 400 mL of 5 mg/mL GPRT-C37-H6 fusion protein, prepared by Professor
Tom Tolbert was added to the dialysis bag. The bag was placed into 1L 25 mM potassium
phosphate pH 7.8, and the cleavage reaction was initiated by adding b-mercaptoethanol to
a final concentration of 1 mM. The reaction was gentle stirred and incubated at room
temperature. It was monitored after 30 min, 1, 2 and 17 hours by running a 17 %
acrylamide gel under denaturing conditions.
2.5. Synthesis of the diamide linker (1)
4,7,10-trioxa-1,13-tridecanediamine (0.16 mL, 9 x 10-4 mol) was added under inert
atmosphere to (-)-ethyl L-lactate (1 mL, 4.5 x 10-3 mol, 5 equiv). The reaction mixture
was first left at room temperature, then heated at 65 °C and finally at 105 °C until the
starting material was gone. Reaction duration: 5 days. The reaction was followed using
CH3CH2OCOCH3:CH3OH/9:1.
* TEV protease concentration was determined theoretically using its absorbance of 0.009
at l(280) following reference 13.
217
3. RESULTS AND DISCUSSION
3.1. Cloning of enfurvitide (Fuzeon) into pET-28a(+)
The gel obtained showed the formation of Fuzeon DNA (Figure 2). With this result it was
concluded that the desired DNA fragment was successfully inserted into pET-28a(+)
plasmid.
Figure 2. Fuzeon DNA from pET-28a(+) plasmid.
3.2. Construction of the Fusion Plasmid
The analytical gel run after the PCR reaction was analyzed at different moments to
confirm that the Fuzeon DNA was running at a different Rf than the control. From this
study it was believed that the primers were able to anneal between them during the PCR
reaction in the absent of a vector, since the control run at a different Rf than the original





Figure 3. PCR reaction analysis.
Single digestions of the plasmid using EcoRI and HindIII were analyzed after 2 hours to
confirm the activity of the restriction enzymes. The 2% agarose gel showed that both the
enzymes were capable to cut the plasmid (Figure 4). The digested plasmid was
successfully purified running a 1% agarose gel which gave two solutions of 50.966 mg/mL
and 29.286 mg/mL. The fragment was also digested, the concentration of the DNA























Figure 4. Single digestion of plasmid pMAL-c2x.
After ligation, transformation made with the ligation mixture of equal volumes of insert
and plasmid did not produced colonies containing the desired plasmid. An appreciable
number of colonies grew in the absence of insert and a few with a small volume of it.
These results reflected that the plasmid could closed in the absent of insert and that its
presence inhibited the plasmid to circularize. If the plasmid could circularize it could mean
that CIP could not cut the phosphate groups leaving the possibility to the ligase to close
the vector. However, although the activity of each restriction enzyme was confirmed,
there still the possibility that one of them is inhibiting the activity of the other. It is also
important to note that the insert was purified using the PCR purification kit from Quigen
instead of using a gel, so there is a chance that the fragment was not appropriately
cleaned.
3.3 TEV Protease cleavage
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The acrylimide gel showed that the cleavage did not finish after 17 hours and a great
amount of the fusion protein was left. It was believed that the dialysis made to the TEV
protease could have decreased its activity.
A second reaction was set up without dialysis of TEV protease and following the
procedure previously mentioned. The reaction was monitored after 30 min, 1, 2, 4 and 19
hours by running a 17 % acrylimide gel under denaturing conditions (Figure 5).
Figure 5. Cleavage of GPRT-C37-H6 fusion protein by TEV protease
The gel showed that the protein cleaved more fusion protein than in the previous study but
it did not take the reaction to completion.
The poor activity obtained could have been caused by using a small quantity of the TEV
protease or because this protein had a low specific activity.




30min 1h   2h     4h    19h
221
It was found that in order to get the reaction to completion, it has to be heated at 105 °C,
in which also the distillation of the ethanol formed is favored. Flash chromatography will
be necessary to separate the desired product from what is believed to be the monoamide
product.
4. CONCLUSIONS
The pET28a(+) contains the DNA sequence that will express Fuzeon and it can be used to
clone this fragment in order to insert it in the plasmid desired, in this case pMAL-c2x that
contains the sequence for the protein partner MPB.
The purification method used to purified Fuzeon DNA after its double digestion gave a
small concentration of DNA, so a different method, like gel purification, should be tried in
order to improve the yield.
Colonies containing the plasmid desired were not obtained. pMAL-c2x circularize in the
absent of insert and a few colonies are obtained in its presence.
The TEV protease used in this study can not be used to cleave the fusion protein desired
(MPB-Fuzeon). It will be necessary to express new protease with a high specific activity.
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The synthesis of the diamide linker should be run at 105 °C in order to get into
completion. The proposed synthesis seems to give the monoamide linker as a byproduct
and flash chromatography is required to purify the product.
5. FUTURE WORK
The digestion of the plasmid will be made by adding one by one the restriction enzymes,
with heat inactivation after 1 hour of reaction of one and before the addition of the
second. This process will assure that both the enzymes will cut the plasmid. If the desired
colonies are still not obtained, there will be a big probability that CIP is the cause of the
problem.
Purification of the DNA fragment after digestion will be achieved by gel purification which
is believed to achieve better results.
The synthesis of the diamide linker will be run at 105 °C. If a poor yield is obtained after
flash purification a second reaction will be used to obtain the diamide linker. The
alternative reaction uses lithium aluminium hydrade (LiAlH4) to deprotonate the nitrogens
of 4,7,10-trioxa-1,13-tridecanediamine, making it a better nucleophile to attack the
carbonyl in the (-)-ethyl L-lactatexli.
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